ClinicalTrials.gg
RecruitingNCT07364474Updated Oct 23, 2026

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

An interventional study of Melphalan through Percutaneous Hepatic Perfusion and Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab in Uveal Melanoma, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Basic science

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 23, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
109th of 163
20 · median 36
Started
2026
with 6 others
No phase
6 of 191
1 open now
Primary completion
2027-12
later than 30 of 50 live
Registered
187th of 191
by date

Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 109th largest by planned enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2026, is one of 6 with no phase, reaches primary completion later than 30 of the 50 other live ones, and was the 187th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with Uveal Melanoma that has metastasized to the liver.

Read the detailed description

Biopsies and blood samples will be collected before treatment to establish baseline measurements. Patients will then receive either a single dose of Melphalan via Percutaneous Hepatic Perfusion (PHP) or a single dose of Melphalan via Percutaneous Hepatic Perfusion (PHP) in combination with Ipilimumab and Nivolumab per standard of care and return 21-28 days later for a follow-up biopsy and peripheral blood draw. Baseline and post-treatment samples will be compared to evaluate the immune response.

03

Conditions studied

  • Uveal Melanoma

Keywords

  • Uveal Melanoma
  • Uveal Melanoma, Metastatic
  • Uveal Melanoma, Metastatic to liver
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has or cytologically confirmed diagnosis of uveal melanoma to the liver and is determined to be a candidate for percutaneous hepatic perfusion with melphalan
  • In Cohort B only: patient is determined to be a candidate for percutaneous hepatic perfusion with melphalan combined with Ipilimumab and Nivolumab
  • The subject has read, signed and dated the Form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject.
  • Age > 18 years at date of informed consent signature having the ability to comply with the protocol.
  • Contrast-enhanced cross-sectional imaging of the abdomen (either CT or MRI) obtained within two months prior to study enrollment
  • Measurable metastatic disease. Subject must have at least one site of metastatic disease ≥ 1 cm in size and amenable to percutaneous image-guided
  • > 12 weeks.
  • (ECOG) Performance Status of 0 or 1
  • Laboratory requirements:
  • (ANC) > 1 x 109/L
  • > 75 x 109/L
  • (ALT) / Aspartate aminotransferase (AST) \< 5 x
  • Total \<3 mg/dL
  • (INR) \<1.7
  • (GFR) >30 ml/min

Exclusion criteria

Exclusion Criteria:

  • Lesion to undergo cannot have undergone prior radiation therapy or other locoregional therapy
  • Continued adverse events from a previously administered chemotherapeutic agents. Grade 1 adverse events and ongoing toxicities such as alopecia are exempt
  • Treatment with systemic exceeding the equivalent of 10 mg/day of prednisone or other systemic medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, and anti-tumor necrosis factor [anti-tumor necrosis factor (TNF)] agents) within 2 weeks prior to Day 1, or anticipated requirement for systemic immunosuppressive medications exceeding the equivalent of 10 mg/day of prednisone during the trial
  • Patients who receive acute, low-dose, systemic corticosteroid medications (e.g., a one-time dose of dexamethasone for nausea) or for prevention of reactions to contrast agents may be enrolled in the trial.
  • Anticoagulant or anti- medication that cannot be interrupted prior to biopsy
  • Pregnant or lactating
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that the use of an drug or that could affect the interpretation of the results or render the patient at high risk from treatment complications.
  • Treatment with systemic immunostimulatory agents (including but not limited to interferon(IFN)s, interleukin [IL]-2) within 6 weeks or five half- lives of the drug, whichever was shorter, prior to Day 1.
  • Prior treatment with immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies, anti-LAG-3 antibodies, within the past three months. Prior treatment with tebentafusp is allowed with no required.
  • Treatment with any investigational systemic medication within at least one month prior to biopsy. If an investigational agent is an immune checkpoint inhibitor, a three-month washout is required. Prior treatment with Darovasertib and Crizotinib is allowed with no washout period required.
  • Signs or symptoms of infection within 2 weeks prior to Day 1.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Melphalan through Percutaneous Hepatic Perfusion (PHP)

    Participants will receive PHP alone per standard of care.

    Drug: Melphalan through Percutaneous Hepatic Perfusion

  • Active comparator
    Melphalan through Percutaneous Hepatic Perfusion (PHP) in Combination with Ipilimumab and Nivolumab

    Participants will receive PHP in combination with Ipilimumab and Nivolumab per standard of care.

    Drug: Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab

Interventions

  • DrugMelphalan through Percutaneous Hepatic Perfusion

    Melphalan through Percutaneous Hepatic Perfusion will be received as standard of care.

  • DrugMelphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab

    Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab will be received as standard of care.

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Intratumoral CXCL13⁺ CD8⁺ T-cell infiltration following Percutaneous Hepatic Perfusion (PHP) or Percutaneous Hepatic Perfusion (PHP) in combination with Ipilimumab and Nivolumab.

    Change in the percentage of CXCL13⁺ CD8⁺ T cells in tumor biopsies between Day 0 (pre-treatment) and Day 28-42 (approximately 3-4 weeks post-treatment), as measured by single-cell RNA sequencing.

    Time frame: 3-4 weeks post treatment

Secondary outcomes

  1. Antigen-presenting cell (APC) populations and their activation state in the tumor microenvironment.

    Comparison of proportions and activation markers of dendritic cells and other APC subsets in pre-treatment (Day 0) and post-treatment (Day 28-42) tumor biopsies.

    Time frame: 28-42 day tumor biopsies

  2. T-cell infiltration in tumor and adjacent hepatic parenchyma.

    Change in FOXP3⁺ regulatory T-cell infiltration between pre-treatment (Day 0) and post-treatment (Day 28-42) tumor and parenchymal biopsies.

    Time frame: 28-42 days post treatment

  3. Single-cell RNA sequencing derived frequency of macrophages and myeloid-derived suppressor cells (MDSCs)

    Change in the frequency of macrophages and myeloid-derived suppressor cells (MDSCs) between pre-treatment (Day 0) and post-treatment (Day 28-42) samples as assessed by single-cell RNA sequencing.

    Time frame: 28-42 days post treatment

  4. Single-cell RNA sequencing derived phenotype of macrophages and myeloid-derived suppressor cells (MDSCs)

    Change in the phenotype of macrophages and myeloid-derived suppressor cells (MDSCs) between pre-treatment (Day 0) and post-treatment (Day 28-42) samples.

    Time frame: 28-42 days post treatment

  5. Immune cell populations with molecular and biochemical features of tissue and peripheral blood.

    Correlation between tissue-based immune cell changes and peripheral biomarkers (e.g. cytokine expression (ng/ml), ctDNA (mtm/ml)) assessed at Day 0 and Day 28-42, and with hepatic radiologic response assessed on CT/MRI as per clinical standard of care .

    Time frame: 28-42 days post treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: alawless@mgb.org . The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication.

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 23, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Sep 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
10→20
Oct 23, 2026
Eligibility
1 inclusion criterion added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • AddedIn Cohort B only: patient is determined to be a candidate for percutaneous hepatic perfusion with melphalan combined with Ipilimumab and Nivolumab
Exclusion criteria
  • EditedTreatmentPrior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, anti-LAG-3 antibodies, within the past three months. Prior treatment with tebentafusp is allowed with no washout period required.
Oct 23, 2026
Interventions
Added Drug: Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab. Arm changed Melphalan through Percutaneous Hepatic Perfusion→Melphalan through Percutaneous Hepatic Perfusion (PHP). Arms added: Melphalan through Percutaneous Hepatic Perfusion (PHP) in Combination with Ipilimumab and Nivolumab
Oct 23, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedIntratumoral CXCL13⁺ CD8⁺ T-cell infiltration following Percutaneous Hepatic Perfusion (PHP) or Percutaneous Hepatic Perfusion (PHP) in combination with Ipilimumab and Nivolumab.Time frame: 3-4 weeks post treatment
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Enrollment 10→20
    Eligibility 1 inclusion criterion added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • AddedIn Cohort B only: patient is determined to be a candidate for percutaneous hepatic perfusion with melphalan combined with Ipilimumab and Nivolumab
    Exclusion criteria
    • EditedTreatmentPrior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, anti-LAG-3 antibodies, within the past three months. Prior treatment with tebentafusp is allowed with no washout period required.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedIntratumoral CXCL13⁺ CD8⁺ T-cell infiltration following Percutaneous Hepatic Perfusion (PHP) or Percutaneous Hepatic Perfusion (PHP) in combination with Ipilimumab and Nivolumab.Time frame: 3-4 weeks post treatment
    Interventions Added Drug: Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab. Arm changed Melphalan through Percutaneous Hepatic Perfusion→Melphalan through Percutaneous Hepatic Perfusion (PHP). Arms added: Melphalan through Percutaneous Hepatic Perfusion (PHP) in Combination with Ipilimumab and Nivolumab
    + 4 other changes: index terms, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07364474
Responsible party
Eric Wehrenberg-Klee, MD (Dana-Farber/Harvard Cancer Center Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jan 23, 2026
Start date
Jan 27, 2026
Primary completion
Dec 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Aleigha Lawless
Contact
alawless@mgb.org
617-643-3578
Juliane A Andrade Czapla
Contact
jczapla@mgh.harvard.edu
Eric Wehrenberg-Klee, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion